Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma

Alessandra Soriani; Cinzia Fionda; Biancamaria Ricci; Maria Luisa Iannitto; Marco Cippitelli; Angela Santoni

doi:10.4161/onci.26663

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma

Oncoimmunology. 2013 Dec 1;2(12):e26663. doi: 10.4161/onci.26663. Epub 2013 Oct 22.

Authors

Alessandra Soriani¹, Cinzia Fionda¹, Biancamaria Ricci¹, Maria Luisa Iannitto¹, Marco Cippitelli¹, Angela Santoni¹

Affiliation

¹ Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy.

Abstract

Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and DNAM-1 ligands on the surface of cancer cells, endowing them with the capacity to activate potent antitumor natural killer-cell responses.

Keywords: DNAM-1; NK cells; NKG2D; multiple myeloma; tumor immunology.